Lu Bin, Lu Chaoyun, Sun Zheng, Qu Caiping, Chen Ji, Hua Zhaolai, Tong Ruimin, Zhang Junfeng
1 Oncology, Yangzhong People's Hospital, Yangzhong, China.
2 Oncology, Yangzhong Cancer Institute, Yangzhong, China.
J Int Med Res. 2019 May;47(5):2207-2214. doi: 10.1177/0300060519827191. Epub 2019 Apr 16.
To investigate the safety and efficacy of acitinib mesylate combined with chemotherapy in the treatment of patients with gastroesophageal junction adenocarcinoma.
A total of 119 patients with gastroesophageal junction adenocarcinoma were enrolled and randomized into an experimental group (n = 60) and a control group (n = 59). Both groups were treated with a combination of taxane, irinotecan and fluorouracil, while the experimental group also received acitinib mesylate. The clinical efficacy, survival time and adverse reactions of patients in two groups were recorded and analyzed.
The total remission rate in the experimental group and the control group was 15.79% and 3.23%, respectively; the disease control rate was 73.68% and 54.84%, respectively; and progression-free survival was 3.72 months (1-13.5 months) and 3.04 months (1-6 months), respectively. Overall survival was 13.66 months (5-24 months) and 10.08 months (6.5-19.5 months), in the experimental group and the control group, respectively. In addition, the incidence of adverse events in the experimental group was significantly lower than that in the control group.
Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control.
探讨甲磺酸阿西替尼联合化疗治疗胃食管交界腺癌患者的安全性和疗效。
共纳入119例胃食管交界腺癌患者，随机分为试验组（n = 60）和对照组（n = 59）。两组均采用紫杉烷、伊立替康和氟尿嘧啶联合治疗，试验组同时接受甲磺酸阿西替尼治疗。记录并分析两组患者的临床疗效、生存时间及不良反应。
试验组和对照组的总缓解率分别为15.79%和3.23%；疾病控制率分别为73.68%和54.84%；无进展生存期分别为3.72个月（1 - 13.5个月）和3.04个月（1 - 6个月）。试验组和对照组的总生存期分别为13.66个月（5 - 24个月）和10.08个月（6.5 - 19.5个月）。此外，试验组不良事件的发生率显著低于对照组。
甲磺酸阿帕替尼联合化疗治疗胃食管交界腺癌患者安全有效，与对照组相比生存获益有所改善。
